Presentations

• Renaud La Joie
  MRI biomarkers to measure LATE in vivo

  

   

• Gil Rabinovici
  Clinical Impact of Amyloid PET in Diverse Medicare Beneficiaries with Cognitive Impairment: Preliminary Results from New IDEAS

• Charles Windon
  Learning from Real-World Data Platforms: Insights into Care and Representation in Research Through ALZ-NET and New IDEAS

• Renaud La Joie
  Panel discussion: Neuroimaging in ADRD: Reflecting on 20 years of progress to design better studies  in 2024 and beyond
   
• Ganna Blazhenets
  Reproducibility of Centiloid Values in Real-World Amyloid PET Data: Comparison of the Imaging Dementia-Evidence for Amyloid Scanning (IDEAS) to Four Large Research Datasets
   
• Julien Lagarde
  Amyloid-PET in patients with a clinical diagnosis of sporadic early versus late-onset AD: comparison of the LEADS and ADNI cohorts
   
• Renaud La Joie
  Introduction to PET quantification and Centiloids
   
• David Soleimani-Meigooni​
  Clinician Experience with Amyloid PET Visual Read and Centiloid Quantitation
   
• Leslie Gaynor
  Medial temporal lobe subregional atrophy patterns in presymptomatic and symptomatic genetic frontotemporal lobar degeneration